Corvus Pharmaceuticals CRVS Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by Corvus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's net gains (losses) on investments?
- Corvus Pharmaceuticals (CRVS) reported net gains (losses) on investments of -$599K in Q1 2026.
- How has Corvus Pharmaceuticals's net gains (losses) on investments changed year-over-year?
- Corvus Pharmaceuticals's net gains (losses) on investments decreased by 11.1% year-over-year, from -$539K to -$599K.
- What is the long-term trend for Corvus Pharmaceuticals's net gains (losses) on investments?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's net gains (losses) on investments has grown at a -20.2% compound annual growth rate (CAGR), from -$4.83M to -$1.96M.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.